Abstract
DTC is considered the most common endocrine neoplasm, and {sup 131}I therapy has been proven to be an important component in the management strategy. Currently, most research focuses on the adverse effects of radiation exposure to {sup 131}I therapy. Some results, based on large-scale and long-term investigation,show new information. Although {sup 131}I therapies are usually well tolerated, clinicians involved in the management of DTC need to be aware of the potential toxicity of {sup 131}I and take all measures to reduce these effects to a minimum. The aim of this review is to present the adverse effects of {sup 131}I therapy for DTC. (authors)
Wenli, Dai;
Bangping, Cui
[1]
- Department of Nuclear Medicine, the First College of Clinical Medical Science, Three Gorges University, Yichang Central People's Hospital (China)
Citation Formats
Wenli, Dai, and Bangping, Cui.
Adverse effects of {sup 131}I therapy for differentiated thyroid cancer.
China: N. p.,
2012.
Web.
Wenli, Dai, & Bangping, Cui.
Adverse effects of {sup 131}I therapy for differentiated thyroid cancer.
China.
Wenli, Dai, and Bangping, Cui.
2012.
"Adverse effects of {sup 131}I therapy for differentiated thyroid cancer."
China.
@misc{etde_22405718,
title = {Adverse effects of {sup 131}I therapy for differentiated thyroid cancer}
author = {Wenli, Dai, and Bangping, Cui}
abstractNote = {DTC is considered the most common endocrine neoplasm, and {sup 131}I therapy has been proven to be an important component in the management strategy. Currently, most research focuses on the adverse effects of radiation exposure to {sup 131}I therapy. Some results, based on large-scale and long-term investigation,show new information. Although {sup 131}I therapies are usually well tolerated, clinicians involved in the management of DTC need to be aware of the potential toxicity of {sup 131}I and take all measures to reduce these effects to a minimum. The aim of this review is to present the adverse effects of {sup 131}I therapy for DTC. (authors)}
journal = []
issue = {6}
volume = {32}
journal type = {AC}
place = {China}
year = {2012}
month = {Dec}
}
title = {Adverse effects of {sup 131}I therapy for differentiated thyroid cancer}
author = {Wenli, Dai, and Bangping, Cui}
abstractNote = {DTC is considered the most common endocrine neoplasm, and {sup 131}I therapy has been proven to be an important component in the management strategy. Currently, most research focuses on the adverse effects of radiation exposure to {sup 131}I therapy. Some results, based on large-scale and long-term investigation,show new information. Although {sup 131}I therapies are usually well tolerated, clinicians involved in the management of DTC need to be aware of the potential toxicity of {sup 131}I and take all measures to reduce these effects to a minimum. The aim of this review is to present the adverse effects of {sup 131}I therapy for DTC. (authors)}
journal = []
issue = {6}
volume = {32}
journal type = {AC}
place = {China}
year = {2012}
month = {Dec}
}